British healthcare workers will on Thursday begin taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one U.S. President Donald Trump says he has been taking.
The ‘COPCOV’ study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and South America to determine if chloroquine and hydroxychloroquine are effective in preventing the novel coronavirus.
Demand for hydroxychloroquine surged after Trump touted it in early April. Earlier this week the U.S. leader said he was now taking the drug as a preventive medicine against the virus despite medical warnings about its use.
The trial, led by the University of Oxford with the support of the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, will open to British participants at hospital sites in Brighton and Oxford on Thursday and involve those who are in close contact with patients with proven or suspected COVID-19.
“We really do not know if chloroquine or hydroxychloroquine are beneficial or harmful against COVID-19,” said the University of Oxford’s Professor Nicholas White, the study’s co-principal investigator, who is based at MORU.
“The best way to find out if they are effective in preventing COVID-19 is in a randomised clinical trial.”
The COPCOV team said laboratory evidence showed the anti-malarial drugs might be effective in preventing or treating COVID-19 but there was no conclusive proof.
U.S. regulators have authorized the emergency use of hydroxlychloroquine for coronavirus patients but the U.S. Food and Drug Administration has warned against the use of it in COVID-19 patients outside of the hospital or clinical trials due to the risk of serious heart rhythm problems.